Trial Profile
A Single-Dose, Randomized, Open-Label, Two-Treatment, Two-Period, Two-Cohort, Crossover Study to Assess the Bioequivalence of Xian Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects Compared With Gurabo Risperdal Tablets
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Aggression; Autistic disorder; Bipolar disorders; Dementia; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Xian-Janssen
- 27 Feb 2018 Planned primary completion date changed from 27 Apr 2018 to 2 Jan 2018.
- 27 Feb 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 21 Dec 2017 Status changed from not yet recruiting to recruiting.